Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 11/20 | 0.43 |
| ▸ | ACACA | Q13085 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854241 | 0.83 | ACACB (0.43) | DRD2ACACBACACANPC1RAB9A | |
| SCHEMBL13741883 | 0.76 | KMT2A (0.56) | DRD2ACACBACACA | |
| SCHEMBL5123798 | 0.76 | ACACB (0.51) | DRD2ACACBACACACKS1BSKP1 | |
| SCHEMBL3853256 | 0.74 | KDM1A (0.39) | — | |
| Formic Acid SCHEMBL28082234 | 0.73 | KMT2A (0.51) | DRD2ACACBACACATDP1CKS1B | |
| SCHEMBL4377073 | 0.73 | KMT2A (0.56) | DRD2ACACBACACATDP1CKS1B | |
| SCHEMBL3816616 | 0.73 | KMT2A (0.56) | DRD2ACACBACACATDP1CKS1B | |
| SCHEMBL190838 | 0.73 | KMT2A (0.56) | DRD2ACACBACACATDP1CKS1B | |
| SCHEMBL3942686 | 0.73 | KMT2A (0.56) | DRD2ACACBACACATDP1CKS1B | |
| SCHEMBL5126676 | 0.72 | KMT2A (0.50) | DRD2ACACBACACACKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007067817-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | DRD2 4395/4885ACACB 46/4885ACACA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.